Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced a change in the clinical development program of fremanezumab
in chronic cluster headache. The ENFORCE Phase III clinical development
program includes a chronic cluster headache study, an episodic cluster
headache study, and a long-term safety study. A pre-specified futility
analysis of the chronic cluster headache study revealed that the primary
endpoint of mean change from baseline in the monthly average number of
cluster headache attacks during the 12-week treatment period is unlikely
to be met. There were no safety concerns observed with fremanezumab
treatment in the trial.

Based on the study meeting the futility criteria, the Company will
discontinue the trial for chronic cluster headache. Chronic Cluster
Headache patients who participate in the long-term safety study, will
discontinue their participation in the long-term safety study as well.
The episodic cluster headache study is not affected and continues as

“While we are disappointed with this outcome, we remain optimistic that
fremanezumab could have clinical benefits in additional conditions,
beyond migraine, where calcitonin gene-related peptide (CGRP) plays a
contributory role in their pathophysiology. We would like to thank the
patients and investigators for their participation in the Chronic
Cluster Clinical Trial,” said Tushar Shah, M.D., Senior Vice President,
Head of Global Specialty Clinical Development at Teva.

Fremanezumab is currently under review by the U.S. Food and Drug
Administration (FDA), with an action date of September 16, 2018, and by
the European Medicines Agency (EMA), as a quarterly or monthly injection
for the preventive treatment of migraine in adults.

About Fremanezumab

Fremanezumab is a monoclonal antibody targeting the CGRP (calcitonin
gene-related peptide) ligand, currently under review by the U.S. Food
and Drug Administration (FDA) and the European Medicines Agency (EMA) as
a quarterly or monthly injection for the preventive treatment of
migraine in adults.

Fremanezumab is also being investigated as a preventive treatment for
several additional disorders including cluster headache and post
traumatic headache disorder.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,800
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva’s net
revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
regarding Fremanezumab, which are based on management’s current beliefs
and expectations and are subject to substantial risks and uncertainties,
both known and unknown, that could cause our future results, performance
or achievements to differ significantly from that expressed or implied
by such forward-looking statements. Important factors that could cause
or contribute to such differences include risks relating to:

and other factors discussed in our Annual Report on Form 10-K for the
year ended December 31, 2017, including in the section captioned “Risk
Factors,” and in our other filings with the U.S. Securities and Exchange
Commission, which are available at www.sec.gov
and www.tevapharm.com.
Forward-looking statements speak only as of the date on which they are
made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise. You
are cautioned not to put undue reliance on these forward-looking

View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005199/en/